HomepageAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
$Â 24,86
Na sluitingstijd:(4,58%)-1,14
$Â 23,72
Gesloten: 16 mei, 18:43:06 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 24,32
Dag-range
$Â 24,20 - $Â 24,90
Jaar-range
$Â 22,64 - $Â 53,96
Beurswaarde
1,17Â mld. USD
Gem. volume
639,87K
Koers/winst
9,02
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 170,53Â mln. | -0,76% |
Bedrijfskosten | 47,96Â mln. | 13,94% |
Netto inkomsten | 25,28Â mln. | -41,44% |
Netto winstmarge | 14,83 | -40,99% |
Winst per aandeel | 0,74 | -28,85% |
EBITDA | 50,90Â mln. | -16,54% |
Effectief belastingtarief | 18,07% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 236,88Â mln. | -18,19% |
Totale activa | 1,63Â mld. | 3,30% |
Totale passiva | 874,99Â mln. | -2,99% |
Totaal aandelenvermogen | 751,28 mln. | — |
Uitstaande aandelen | 47,14 mln. | — |
Koers-boekwaardeverhouding | 1,54 | — |
Rendement op activa | 5,82% | — |
Rendement op kapitaal | 6,69% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 25,28Â mln. | -41,44% |
Operationele kasstroom | 35,08Â mln. | -36,56% |
Kasstroom uit beleggingen | 10,48Â mln. | -31,21% |
Kasstroom uit financiering | -14,50Â mln. | -6,80% |
Nettomutatie in liquide middelen | 31,17Â mln. | -45,17% |
Vrije kasstroom | 16,94Â mln. | -57,15% |
Over
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Opgericht
1996
Hoofdvestiging
Website
Werknemers
2.028
